Akorn long-term fundamentals remain unchanged, says Leerink Leerink says Akron's long-term fundamentals remain unchanged following the company's FY13 guidance call. The firm thinks management met expectations on the top line, provided a reasonable explanation on margins and slightly disappointed on manufacturing capacity expansion. Leerink raised its price target for Akorn shares to $16 from $14-$15 and keeps an Outperform rating on the name.
Akorn launches Myorisan 30 mg Capsules Akorn announced that it has launched the recently-approved 30 mg strength of Myorisan. This launch further builds the Myorisan product portfolio that also includes 10 mg, 20 mg and 40 mg capsules.